NASDAQ
KMTS
Last Price
US $24.18
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Kestra Medical Technologies, Ltd. cash flow to debt ratio of -175.14% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Kestra Medical Technologies, Ltd.'s free cash flow has decreased 19.41% from $-84.75M last year to $-101.20M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Kestra Medical Technologies, Ltd.'s debt to equity ratio is 0.16, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
Kestra Medical Technologies, Ltd.'s debt has increased relative to shareholder equity from -0.22 last year to 0.16 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
Kestra Medical Technologies, Ltd. has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
Kestra Medical Technologies, Ltd.'s interest coverage ratio is -19.25, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial stability - Profit margin growth.
Kestra Medical Technologies, Ltd.'s profit margin has increased (-48.88%) in the last year from -338.39% to -172.99%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Kestra Medical Technologies, Ltd.'s short-term assets of $255.33M exceed its short-term liabilities of $37.98M
Decreasing performance - ROA.
Kestra Medical Technologies, Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Kestra Medical Technologies, Ltd.'s return on equity of -68.83%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Kestra Medical Technologies, Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Kestra Medical Technologies, Ltd. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Kestra Medical Technologies, Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Kestra Medical Technologies, Ltd. has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Kestra Medical Technologies, Ltd.'s yearly earnings has decreased 20.92% since last year from $-94.12M to $-113.81M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Kestra Medical Technologies, Ltd.'s yearly revenue has increased 115.05% since last year from $27.81M to $59.81M, signaling increasing performance
Decreasing performance - ROIC.
ROIC -42.69% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Kestra Medical Technologies, Ltd. has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
Kestra Medical Technologies, Ltd. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Kestra Medical Technologies, Ltd. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Kestra Medical Technologies, Ltd. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Kestra Medical Technologies, Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Kestra Medical Technologies, Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Kestra Medical Technologies, Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Kestra Medical Technologies, Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Kestra Medical Technologies, Ltd. has a price-to-book ratio of 4.44x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Kestra Medical Technologies, Ltd. has a price-to-sales ratio of 15.26x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-68.83%
Return on equity
ROIC: -42.69%
Valuation History
-6.6X
Price to Earnings
EV/EBITDA: -9.9X
Cash flow
Profit margin
-21.70%
(FY vs FY)
Cash flow Y/Y
-21.31%
(FY vs FY)
Fair Value
Market $24.18
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.